Background: Existing literature suggests that metformin, the most commonly used biguanide, may lower colorectal cancer risk. Because most colorectal cancers originate in precancerous adenomas, we examined whether metformin use lowered colorectal adenoma risk after polypectomy in patients with type-2 diabetes.

Methods: Retrospective cohort study of 40- to 89-year-old Kaiser Permanente Northern California patients who had type 2 diabetes, and ≥1 adenoma detected at baseline colonoscopy during 2000 to 2009 and a repeat colonoscopy 1 to 10 years from baseline adenoma diagnosis through 2012. Cox models evaluated the association between metformin use during follow-up and subsequent adenoma diagnoses, controlling for age, race/ethnicity, sex, body mass index, and repeat examination indication.

Results: Study included 2,412 patients followed for a median of 4.5 years; cumulatively, 1,117 (46%) patients had ≥1 adenoma at repeat colonoscopy. Compared with patients not receiving diabetes medications (n = 1,578), metformin-only use (n = 457) was associated with lower adenoma recurrence risk [adjusted HR, 0.76; 95% confidence interval (CI), 0.65–0.89], and the association was stronger with increasing total metformin dose [quartile (Q) 1: HR, 0.90; 95% CI, 0.72–1.12; Q2: HR, 0.89; 95% CI, 0.70–1.12; Q3: HR, 0.80; 95% CI, 0.63–1.01; Q4: HR, 0.50; 95% CI, 0.42–0.60, Ptrend < 0.001]. Findings were unchanged in sensitivity analyses, including evaluating only outcomes during the 3- to 10-year period from baseline.

Conclusion: Our study suggests a potential benefit of metformin use in lowering the risk of subsequent adenomas after polypectomy in patients with type 2 diabetes.

Impact: Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions, reinforcing the potential additional benefits of its use. Cancer Epidemiol Biomarkers Prev; 24(11); 1692–8. ©2015 AACR.

This article is featured in Highlights of This Issue, p. 1641

Colorectal cancer is the second leading cause of cancer-related death in the United States (1), with most originating as precancerous adenomas (2). Many patients in whom colorectal adenomas have been removed develop subsequent lesions (3–5). In the United States, based on Clinical Outcomes Research Initiative data, surveillance procedures aimed at detecting such new or recurrent lesions account for about 22% of all colonoscopies among persons 50 years and older, and is the most common reason for colonoscopy among those 75 years and older (6, 7). Thus, therapies that reduce adenoma recurrence may reduce both colorectal cancer risk and the need for surveillance colonoscopy.

Previous studies have found that commonly used medications, such as aspirin and celecoxib, may reduce adenoma and colorectal cancer risk (8–11), but there is a paucity of published studies evaluating metformin's effect and its potential chemopreventive role. Metformin is the most commonly prescribed drug for the prevention or treatment of type 2 diabetes mellitus and associated conditions (12). Studies show that a diagnosis of diabetes is associated with an increased risk of diagnosis with colorectal adenomas and adenocarcinoma (13, 14). A number of studies have suggested that metformin may reduce colorectal cancer risk (15–18), but others have found no association (19, 20). However, there is limited literature on metformin use and colorectal adenoma risk (21), and no prior studies have examined whether metformin reduces the risk of adenoma formation after polypectomy. In this study, we examined the relationship between metformin use and detection of new or recurrent adenomas at follow-up examination after polypectomy in patients with type 2 diabetes.

Study design and setting

This is a retrospective cohort study of patients receiving care in Kaiser Permanente Northern California (KPNC), an integrated healthcare delivery organization serving approximately 3.3 million people in urban, suburban, and semirural regions within a large geographic area. The integrated structure allows access to stable enrolled populations for longitudinal studies. The study was approved by the Institutional Review Boards of KPNC and the University of Pennsylvania.

Population

The study cohort was comprised of patients with type 2 diabetes who were 40 to 89 years old at the time they underwent a colonoscopy between January 1, 2000, and December 31, 2009, in which ≥1 histologically confirmed colorectal adenomas were found and removed. Patients were followed from the index examination date to the date of a follow-up colonoscopy on or before December 31, 2012, the last date of follow-up. We restricted the study to patients who had a repeat colonoscopy 1 to 10 years after the index examination (Fig. 1).

Patients with diabetes were identified using the Northern California Kaiser Permanente Diabetes Registry, which was started in 1993 (22). The updated criteria for inclusion in the registry are as follows: (i) one or more prescriptions within the diabetes therapeutic class, one or more inpatient diabetes diagnosis, or two or more outpatient diabetes diagnoses in a prior 5-calendar-year period; or (ii) two or more pertinent abnormal labs [serum glycosylated hemoglobin (HbA1c) ≥6.5%, fasting glucose ≥126 mg/dL, or glucose ≥ 200 mg/dL] in a prior two-calendar-year period. Patients with gestational diabetes, type 1 diabetes, or who were prescribed diabetes medications for indications other than type 2 diabetes, such as lipodystrophy, metabolic syndrome, prediabetes, polycystic ovary syndrome, or amenorrhea, were excluded. Other exclusion criteria were: <2 years of health plan membership before cohort entry; history of colorectal cancer diagnosis or colectomy before or within 1 year after the index colonoscopy; and documented familial colorectal cancer syndromes such as Lynch syndrome or familial adenomatous polyposis.

To focus on new metformin users, we excluded those on diabetes medications more than 1 year before the index colonoscopy. This approach minimizes time-related biases (23) and also minimizes the potential to selectively include lesions that may have been resistant to the effect of metformin, and thus are destined to recur. This approach also minimizes the inclusion of patients who may have had diabetes for longer duration before study baseline or used metformin for indications other than type 2 diabetes. We also excluded patients who discontinued diabetes medication before the index colonoscopy; used metformin for less than 6 months; or used other diabetes medications without metformin (Fig. 1).

Data sources

Information on clinical diagnoses was obtained from electronic databases using International Classification of Disease, Ninth Edition, Clinical Modification (ICD-9-CM) codes. Drug dispensing data were obtained from pharmacy files using National Drug Codes. Receipt of initial and follow-up colonoscopies were ascertained using Current Procedural Terminology and ICD-9-CM codes, as previously described (24). Adenoma diagnosis, location, and histology were obtained from pathology reports using Systematized Nomenclature of Medicine Clinical Terms (SNOMED) codes (24).

Outcome measurements

The primary outcome was colorectal adenoma recurrence, defined as ≥1 histologically confirmed adenoma or adenocarcinoma at the repeat colonoscopy. Person-time was computed from the index colonoscopy date. Adenoma location was classified as right colon (proximal to and including the splenic flexure, irrespective of whether adenomas were detected in the distal colon), left colon/rectum, or unspecified using SNOMED codes (24). The location was unspecified for approximately one third of baseline adenomas.

Exposure measurement

The primary exposure of interest was metformin-only use during the follow-up period based on dispensings. We also evaluated metformin used in combination with other diabetes medications, such as sulfonylureas (any-metformin). We computed the metformin total dose (with or without other diabetes medications) dispensed during the follow-up period to assess dose-related effects; discontinuous dispensing periods were summed together. Total dose quartiles (Q) were calculated among all metformin users as follows: 50–399 (Q1); 400–799 (Q2); 800–1499 (Q3); and ≥1,500 (Q4) grams. We assumed that patients used all dispensed metformin.

Covariates

Information was available on patient age, sex, race/ethnicity, and baseline body mass index (BMI). BMI is related to the risk of type 2 diabetes, type of diabetes medication prescribed, disease severity, and likelihood of receiving colonoscopy (25, 26). The performing physician and colonoscopy indications were derived using previously validated algorithms (27, 28). We obtained serum HbA1c levels from laboratory databases. HbA1c levels correlate with serum glucose levels, which may be related to disease risk (29, 30).

Statistical analyses

We first used the Kaplan–Meier product limit estimator to evaluate the association between metformin use and adenoma recurrence risk. Multilevel Cox proportional hazard models with clustering on the performing provider were used to estimate HRs and 95% confidence intervals (CI) for the association between exposure to metformin in the 1- to 10-year period after the index colonoscopy and risk of adenoma recurrence. The reference group in all analyses was patients who did not receive any diabetes medications during the study period. Multivariable models were adjusted for the covariates noted above, except HbA1c, which was not statistically significantly associated with adenoma recurrence risk (P > 0.05), and did not influence the main effects. We stratified on repeat colonoscopy indication (surveillance vs. diagnostic) on some of our analyses because of statistically significant interaction with metformin use. We also performed analyses according to baseline adenoma location (right vs. left colon) due to a priori interest and possible biologic differences in colorectal lesions according to location (31). In secondary analyses, we evaluated the association between any-metformin exposure (with or without other diabetes medications) and adenoma recurrence risk, as either a binary variable, or according to total dispensed dose quartiles.

We performed several sensitivity analyses, including limiting the cohort to new metformin initiators (n = 2,213), and to those with repeat examinations 3 to 5, or 6 to 10 years from baseline consistent with surveillance recommendations (32). Type 2 diabetes occurs insidiously and patients may remain in a prediabetic state or have undetected diabetes for many years before clinical diagnosis (33–35). We assumed this preclinical phase to be <5 years and performed analyses in which accrued person-time was computed from no further than 5 years before the diabetes diagnosis date. We also assessed the duration of therapy in our sensitivity analyses (Supplementary Table S1). Because of reports of potential gender differences in the association between having diabetes and colorectal neoplasia risk, we performed further analysis stratified on gender (36), although there was no statistically significant gender–metformin interaction observed. We examined and did not find a statistically significant association with level of glycemic control based on an HbA1C of ≤7% versus higher. All analyses were performed using SAS 9.3 software (SAS Institute).

Baseline characteristics

We identified 288,079 patients who were 40- to 89-years-old and had undergone colonoscopy during 2000 to 2009, of whom 95,927 had ≥1 histologically confirmed adenoma. Of those, 2,412 eligible patients with type 2 diabetes were included in the study (Fig. 1). The median time to repeat exam (4.5 years) did not differ significantly across exposures. On average, metformin users were on therapy for 878 days (range, 146–3,066), received 0.99 grams per day (range, 0.10–3.17), and had a total dose of 800 grams (range: 50–5,900) during the study period.

Association with adenoma recurrence risk

A total of 834 patients had used metformin, including 377 patients who received it in combination with other drugs, most commonly sulfonylurea, and 1,578 who did not receive diabetes therapy (Fig. 1). Cumulatively, 196 (42.9%) of the 457 patients on metformin-only had adenoma recurrence compared with 739 (46.8%) patients who did not receive diabetes therapy (untreated; Table 1). In Kaplan–Meier analysis, untreated patients had a higher rate of adenoma recurrence than those on metformin (Fig. 2, log-rank test P < 0.001). Cox modeling showed a 24% lower risk of adenoma recurrence (adjusted HR, 0.76; 95% CI, 0.65–0.89; Table 2) in those on metformin-only. This association was observed in analyses stratified by repeat colonoscopy indication (surveillance n = 1,329, adjusted HR, 0.89; 95% CI, 0.73–1.09; diagnostic n = 1,083, adjusted HR, 0.62; 95% CI, 0.50–0.79; Pinteraction = 0.02), and by location of the index lesion (right colon n = 1,117, adjusted HR, 0.75; 95% CI, 0.62–0.90; left colon/rectum n = 421, adjusted HR, 0.66; 95% CI, 0.41–1.05; Pinteraction = 0.95; Table 2). However, the association was not statistically significant for left colon lesions or surveillance examinations.

In secondary analyses, any-metformin use (alone and in combination with other diabetes medications) was similarly associated with a lower adenoma recurrence risk (adjusted HR, 0.74; CI 0.66–0.84; Table 2). The risk of adenoma recurrence was monotonically lower with increasing total dose. Compared with no therapy, and with increasing quartiles denoting increasing dose, the adjusted HR was 0.90 (95% CI, 0.72–1.12) for Q1, 0.89 (95% CI, 0.70–1.12) for Q2, 0.80 (95% CI, 0.63–1.01) for Q3, and 0.50 (95% CI, 0.42–0.60) for Q4 (Ptrend < 0.001). The findings were similar for analysis of average daily dose dispensed and the duration of therapy (Supplementary Table S1). The associations with metformin use were stable in sensitivity analyses, excluding patients who had used antidiabetes medication before the index colonoscopy, or person-time accrued >5 years before the diabetes diagnosis date (Supplementary Table S2), excluding repeat colonoscopies performed <3 years of index date (Supplementary Table S3), or according to gender (Supplementary Table S4).

We found that, in patients with type 2 diabetes, metformin use was associated with a lower risk of colorectal adenoma recurrence when compared with no diabetes therapy. The observed risk was inversely related to metformin total dose and was stable in various sensitivity analyses, including models that were restricted to new therapy initiators. These findings suggest that, in addition to its established role in treating diabetes and related conditions, metformin use may also confer additional benefits in lowering the risk of adenoma.

The association of metformin with colorectal cancer or adenoma risk is controversial. Our findings are consistent with, and support previous reports that metformin use was associated with colorectal cancer risk. Our findings were stable in various secondary and sensitivity analyses. This study's findings may also suggest a potential explanation for how metformin may lower colorectal cancer risk through the adenoma–carcinoma sequence. Metformin's effect on adenoma risk could be mediated through several posited biologic mechanisms such as mechanistic target of rapamycin (mTOR) pathway inhibition and insulin-like growth factor signaling suppression (37).

There are no previous studies to directly compare with ours, but Lee and colleagues (38) reported that, in patients with type 2 diabetes who had undergone colorectal cancer resection, metformin use was associated with lower odds (OR, 0.27; 95% CI, 0.10–0.76) of recurrent adenoma. Kanadiya and colleagues (21) also reported that metformin use was associated with lower odds (OR, 0.55; 95% CI, 0.34–0.87) of adenoma in a study of 405 patients with type 2 diabetes undergoing screening colonoscopy (n = 148). In contrast, our study examined adenoma risk during the surveillance phase of the cancer care continuum on a large cohort of 2,412 patients, with 834 exposed to metformin. Our design addressed several potential time-related biases of observational studies (23).

Our study has some potential limitations. First, we restricted the follow-up time to the first repeat colonoscopy, which limited the time interval for detecting recurrent lesions as well as our ability for direct causal inference. However, there was no substantive difference in the follow-up time according to exposure group. Also, we could not account for exposure to other potential adenoma chemopreventive strategies, such as COX-2 inhibitors, aspirin and other non-steroidal anti-inflammatory drugs, statins, lifestyle factors, smoking history, and dietary factors such as folic acid and calcium (9–11, 39–41).

In conclusion, we found an inverse association between metformin use and risk of adenoma recurrence in patients with type 2 diabetes that was independent of other factors assessed. These findings suggest a possible role for metformin in the secondary chemoprevention of adenomas.

No potential conflicts of interest were disclosed.

Conception and design: R.A. Pietrofesa, A. Zebrowski, D.A. Corley, C.A. Doubeni

Development of methodology: A.R. Marks, R.A. Pietrofesa, C.D. Jensen, D.A. Corley, C.A. Doubeni

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A.R. Marks, D.A. Corley, C.A. Doubeni

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A.R. Marks, R.A. Pietrofesa, C.D. Jensen, D.A. Corley, C.A. Doubeni

Writing, review, and/or revision of the manuscript: A.R. Marks, R.A. Pietrofesa, C.D. Jensen, A. Zebrowski, D.A. Corley, C.A. Doubeni

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.R. Marks, R.A. Pietrofesa, C.A. Doubeni

Study supervision: D.A. Corley, C.A. Doubeni

The authors thank Sean Hennessy, PharmD, PhD, and James D. Lewis, MD, MSCE, for advice on study design, analysis, and helpful comments and suggestions on the article.

This work was funded in part from the Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania (to C.A. Doubeni). The work was also supported in part by grants K01CA127118 and U01CA151736 (to C.A. Doubeni) and grant U54CA163262 (to C.A. Doubeni and D.A. Corley) from the NCI at the NIH.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Siegel
RL
,
Miller
KD
,
Jemal
A
. 
Cancer statistics, 2015
.
CA Cancer J Clin
2015
;
65
:
5
29
.
2.
Vogelstein
B
,
Fearon
ER
,
Hamilton
SR
,
Kern
SE
,
Preisinger
AC
,
Leppert
M
, et al
Genetic alterations during colorectal-tumor development
.
N Engl J Med
1988
;
319
:
525
32
.
3.
Winawer
SJ
,
Zauber
AG
,
O'Brien
MJ
,
Ho
MN
,
Gottlieb
L
,
Sternberg
SS
, et al
Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup
.
N Engl J Med
1993
;
328
:
901
6
.
4.
van Stolk
RU
,
Beck
GJ
,
Baron
JA
,
Haile
R
,
Summers
R
. 
Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. The polyp prevention study group
.
Gastroenterology
1998
;
115
:
13
8
.
5.
Laiyemo
AO
,
Doubeni
C
,
Brim
H
,
Ashktorab
H
,
Schoen
RE
,
Gupta
S
, et al
Short- and long-term risk of colorectal adenoma recurrence among whites and blacks
.
Gastrointest Endosc
2013
;
77
:
447
54
.
6.
Lieberman
DA
,
Holub
J
,
Eisen
G
,
Kraemer
D
,
Morris
CD
. 
Utilization of colonoscopy in the United States: results from a national consortium
.
Gastrointest Endosc
2005
;
62
:
875
83
.
7.
Lieberman
DA
,
Williams
JL
,
Holub
JL
,
Morris
CD
,
Logan
JR
,
Eisen
GM
, et al
Colonoscopy utilization and outcomes 2000 to 2011
.
Gastrointest Endosc
2014
;
80
:
133
43
.
8.
Sandler
RS
,
Halabi
S
,
Baron
JA
,
Budinger
S
,
Paskett
E
,
Keresztes
R
, et al
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
.
N Engl J Med
2003
;
348
:
883
90
.
9.
Baron
JA
,
Cole
BF
,
Sandler
RS
,
Haile
RW
,
Ahnen
D
,
Bresalier
R
, et al
A randomized trial of aspirin to prevent colorectal adenomas
.
N Engl J Med
2003
;
348
:
891
9
.
10.
Arber
N
,
Eagle
CJ
,
Spicak
J
,
Racz
I
,
Dite
P
,
Hajer
J
, et al
Celecoxib for the prevention of colorectal adenomatous polyps
.
N Engl J Med
2006
;
355
:
885
95
.
11.
Bertagnolli
MM
,
Eagle
CJ
,
Zauber
AG
,
Redston
M
,
Solomon
SD
,
Kim
K
, et al
Celecoxib for the prevention of sporadic colorectal adenomas
.
N Engl J Med
2006
;
355
:
873
84
.
12.
Qaseem
A
,
Humphrey
LL
,
Sweet
DE
,
Starkey
M
,
Shekelle
P
. 
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians
.
Ann Intern Med
2012
;
156
:
218
31
.
13.
Luo
S
,
Li
JY
,
Zhao
LN
,
Yu
T
,
Zhong
W
,
Xia
ZS
, et al
Diabetes mellitus increases the risk of colorectal neoplasia: an updated meta-analysis
.
Clin Res Hepatol Gastroenterol
2015
;
S2210-7401
:
00137
0
.
14.
Guraya
SY
. 
Association of type 2 diabetes mellitus and the risk of colorectal cancer: a meta-analysis and systematic review
.
World J Gastroenterol
2015
;
21
:
6026
31
.
15.
Zhang
ZJ
,
Zheng
ZJ
,
Kan
H
,
Song
Y
,
Cui
W
,
Zhao
G
, et al
Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis
.
Diabetes Care
2011
;
34
:
2323
8
.
16.
Libby
G
,
Donnelly
LA
,
Donnan
PT
,
Alessi
DR
,
Morris
AD
,
Evans
JM
. 
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes
.
Diabetes Care
2009
;
32
:
1620
5
.
17.
Currie
CJ
,
Poole
CD
,
Gale
EA
. 
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
.
Diabetologia
2009
;
52
:
1766
77
.
18.
Lee
MS
,
Hsu
CC
,
Wahlqvist
ML
,
Tsai
HN
,
Chang
YH
,
Huang
YC
. 
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals
.
BMC Cancer
2011
;
11
:
20
.
19.
Smiechowski
B
,
Azoulay
L
,
Yin
H
,
Pollak
MN
,
Suissa
S
. 
The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus
.
Cancer Epidemiol Biomarkers Prev
2013
;
22
:
1877
83
.
20.
Kowall
B
,
Stang
A
,
Rathmann
W
,
Kostev
K
. 
No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK
.
Pharmacoepidemiol Drug Saf
2015
;
24
:
865
74
.
21.
Kanadiya
MK
,
Gohel
TD
,
Sanaka
MR
,
Thota
PN
,
Shubrook
JH
, Jr. 
Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopy
.
J Diabetes Complications
2013
;
27
:
463
6
.
22.
Karter
AJ
,
Ferrara
A
,
Liu
JY
,
Moffet
HH
,
Ackerson
LM
,
Selby
JV
. 
Ethnic disparities in diabetic complications in an insured population
.
JAMA
2002
;
287
:
2519
27
.
23.
Suissa
S
,
Azoulay
L
. 
Metformin and the risk of cancer: time-related biases in observational studies
.
Diabetes Care
2012
;
35
:
2665
73
.
24.
Corley
DA
,
Jensen
CD
,
Marks
AR
,
Zhao
WK
, de
Boer
J
,
Levin
TR
, et al
Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs
.
Clin Gastroenterol Hepatol
2013
;
11
:
172
80
.
25.
Lewis
JD
,
Capra
AM
,
Achacoso
NS
,
Ferrara
A
,
Levin
TR
,
Quesenberry
CP
 Jr
, et al
Medical therapy for diabetes is associated with increased use of lower endoscopy
.
Pharmacoepidemiol Drug Saf
2007
;
16
:
1195
202
.
26.
Rosen
AB
,
Schneider
EC
. 
Colorectal cancer screening disparities related to obesity and gender
.
J Gen Intern Med
2004
;
19
:
332
8
.
27.
Lee
JK
,
Jensen
CD
,
Lee
A
,
Doubeni
CA
,
Zauber
AG
,
Levin
TR
, et al
Development and validation of an algorithm for classifying colonoscopy indication
.
Gastrointest Endosc
2015
;
81
:
575
82 e4
.
28.
Corley
DA
,
Jensen
CD
,
Marks
AR
,
Zhao
WK
,
Lee
JK
,
Doubeni
CA
, et al
Adenoma detection rate and risk of colorectal cancer and death
.
N Engl J Med
2014
;
370
:
1298
306
.
29.
Khaw
KT
,
Wareham
N
,
Bingham
S
,
Luben
R
,
Welch
A
,
Day
N
. 
Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study
.
Cancer Epidemiol Biomarkers Prev
2004
;
13
:
915
9
.
30.
Yang
YX
,
Habel
LA
,
Capra
AM
,
Achacoso
NS
,
Quesenberry
CP
, Jr.,
Ferrara
A
, et al
Serial glycosylated hemoglobin levels and risk of colorectal neoplasia among patients with type 2 diabetes mellitus
.
Cancer Epidemiol Biomarkers Prev
2010
;
19
:
3027
36
.
31.
Laiyemo
AO
,
Doubeni
C
,
Sanderson
AK
, 2nd,
Pinsky
PF
,
Badurdeen
DS
,
Doria-Rose
VP
, et al
Likelihood of missed and recurrent adenomas in the proximal versus the distal colon
.
Gastrointestinal Endosc
2011
;
74
:
253
61
.
32.
Lieberman
DA
,
Rex
DK
,
Winawer
SJ
,
Giardiello
FM
,
Johnson
DA
,
Levin
TR
. 
Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer
.
Gastroenterology
2012
;
143
:
844
57
.
33.
Friedman
SM
,
Vallipuram
J
,
Baswick
B
. 
Incidental findings of elevated random plasma glucose in the ED as a prompt for outpatient diabetes screening: a retrospective study
.
BMJ Open
2013
;
3
:
e003486
.
34.
Meigs
JB
,
Muller
DC
,
Nathan
DM
,
Blake
DR
,
Andres
R
Baltimore Longitudinal Study of A
. 
The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging
.
Diabetes
2003
;
52
:
1475
84
.
35.
Harris
MI
,
Klein
R
,
Welborn
TA
,
Knuiman
MW
. 
Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis
.
Diabetes Care
1992
;
15
:
815
9
.
36.
Campbell
PT
,
Deka
A
,
Jacobs
EJ
,
Newton
CC
,
Hildebrand
JS
,
McCullough
ML
, et al
Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men
.
Gastroenterology
2010
;
139
:
1138
46
.
37.
Pollak
MN
. 
Investigating metformin for cancer prevention and treatment: the end of the beginning
.
Cancer Discov
2012
;
2
:
778
90
.
38.
Lee
JH
,
Jeon
SM
,
Hong
SP
,
Cheon
JH
,
Kim
TI
,
Kim
WH
. 
Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer
.
Dig Liver Dis
2012
;
44
:
1042
7
.
39.
Broughton
T
,
Sington
J
,
Beales
IL
. 
Statin use is associated with a reduced incidence of colorectal adenomatous polyps
.
Int J Colorectal Dis
2013
;
28
:
469
76
.
40.
Cole
BF
,
Baron
JA
,
Sandler
RS
,
Haile
RW
,
Ahnen
DJ
,
Bresalier
RS
, et al
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial
.
JAMA
2007
;
297
:
2351
9
.
41.
Baron
JA
,
Beach
M
,
Mandel
JS
,
van Stolk
RU
,
Haile
RW
,
Sandler
RS
, et al
Calcium supplements for the prevention of colorectal adenomas
.
N Engl J Med
1999
;
340
:
101
7
.